New roles for Smad signaling and phosphatidic acid in the regulation of skeletal muscle mass

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Goodman, Craig A ^a   Hornberger, Troy A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYTOKINE; DIACYLGLYCEROL KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYOSTATIN; PHOSPHATIDIC ACID; PHOSPHOLIPASE D1; SMAD PROTEIN; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN;

ARTICLE; BONE MASS; DISEASE RESISTANCE; ECCENTRIC MUSCLE CONTRACTION; HUMAN; IN VIVO STUDY; METABOLISM; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; MUSCLE MASS; MYOTUBE; PROTEIN FUNCTION; PROTEIN SYNTHESIS; QUALITY OF LIFE; REGULATORY MECHANISM; SKELETAL MUSCLE; SYNTHESIS;

EID: 84899723616     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-20     Document Type: Article

References (82)

1. Lee RC, Wang Z, Heo M, Ross R, Janssen I, Heymsfield SB: Total-body skeletal muscle mass: development and cross-validation of anthropometric prediction models. Am J Clin Nutr 2000, 72:796-803.
2. Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viereck J, Hamilton JA, Ouchi N, LeBrasseur NK, Walsh K: Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 2008, 7:159-72. (Pubitemid 351168553)
3. Seguin R, Nelson ME: The benefits of strength training for older adults. Am J Prev Med 2003, 25:141-9. (Pubitemid 41116508)
4. Srikanthan P, Karlamangla AS: Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab 2011, 96:2898-903.
5. Lynch GS: Tackling Australia's future health problems: developing strategies to combat sarcopenia-age-related muscle wasting and weakness. Intern Med J 2004, 34:294-6.
6. Bonaldo P, Sandri M: Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech 2013, 6:25-39.
7. Sandri M: Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008, 23:160-70.
8. Frost RA, Lang CH: Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. J Appl Physiol 2007, 103:378-87. (Pubitemid 47092315)
9. Bodine SC: mTOR signaling and the molecular adaptation to resistance exercise. Med Sci Sports Exerc 2006, 38:1950-7.
10. Zacharewicz E, Lamon S, Russell AP: MicroRNAs in skeletal muscle and their regulation with exercise, ageing, and disease. Front Physiol 2013, 4:266.
11. Verhees KJP, Pansters NAM, Schols AMWJ, Langen RCJ: Regulation of skeletal muscle plasticity by glycogen synthase kinase-3b: a potential target for the treatment of muscle wasting. Curr Pharm Des 2013, 19:3276-98.
12. Tabebordbar M, Wang ET, Wagers AJ: Skeletal muscle degenerative diseases and strategies for therapeutic muscle repair. Annu Rev Pathol 2013, 8:441-75.
13. Senf SM: Skeletal muscle heat shock protein 70: diverse functions and therapeutic potential for wasting disorders. Front Physiol 2013, 4:330.
14. Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP: Gluco-corticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013, 45:2163-72.
15. Sandri M: Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol 2013, 45:2121-9.
16. Ljubicic V, Jasmin BJ: AMP-activated protein kinase at the nexus of therapeutic skeletal muscle plasticity in Duchenne muscular dystrophy. Trends Mol Med 2013, 19:614-24.
17. Egerman MA, Glass DJ: Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol 2014, 49:59-68.
18. Wallace MA, Lamon S, Russell AP: The regulation and function of the striated muscle activator of rho signaling (STARS) protein. Front Physiol 2012, 3:469.
19. Kumar A, Bhatnagar S, Paul PK: TWEAK and TRAF6 regulate skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care 2012, 15:233-9.
20. Goodman CA, Mayhew DL, Hornberger TA: Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass. Cell Signal 2011, 23:1896-906.
21. Lynch GS, Ryall JG: Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008, 88:729-67. (Pubitemid 351520091)
22. Goodman CA: The Role of mTORC1 in Regulating Protein Synthesis and Skeletal Muscle Mass in Response to Various Mechanical Stimuli. Rev Physiol Biochem Pharmacol 2014.
23. Han HQ, Zhou X, Mitch WE, Goldberg AL: Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol 2013, 45:2333-47.
24. Tsuchida K: The role of myostatin and bone morphogenetic proteins inmuscular disorders. Expert Opin Biol Ther 2006, 6:147-54.
25. Hornberger TA: Mechanotransduction and the regulation of mTORC1 signaling in skeletal muscle. Int J Biochem Cell Biol 2011, 43:1267-76.
26. Jacobs BL, Goodman CA, Hornberger TA: The mechanical activation of mTOR signaling: an emerging role for late endosome/lysosomal targeting. J Muscle Res Cell Motil 2013.
27. Adams GR, Bamman MM: Characterization and regulation of mechanical loading-induced compensatory muscle hypertrophy. Compr Physiol 2012, 2:2829-70.
28. Miyazono K, Maeda S, Imamura T: BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005, 16:251-63. (Pubitemid 40910315)
29. Moustakas A, Heldin C: The regulation of TGFbeta signal transduction. Development 2009, 136:3699-714.
30. McPherron AC, Lawler AM, Lee SJ: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997, 387:83-90. (Pubitemid 27202654)
31. Lee SJ, McPherron AC: Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001, 98:9306-11.
32. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, Shen R, Lalani R, Asa S, Mamita M, Nair G, Arver S, Bhasin S: Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA 1998, 95:14938-43. (Pubitemid 29003735)
33. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee S: Induction of cachexia in mice by systemically administered myostatin. Science 2002, 296:1486-8. (Pubitemid 34553097)
34. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R: Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 2002, 277:49831-40. (Pubitemid 36014431)
35. Elkina Y, von Haehling S, Anker SD, Springer J: The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle 2011, 2:143-51.
36. Ross S, Hill CS: How the Smads regulate transcription. Int J Biochem Cell Biol 2008, 40:383-408. (Pubitemid 351241229)
37. Walton KL, Makanji Y, Harrison CA: New insights into the mechanisms of activin action and inhibition. Mol Cell Endocrinol 2012, 359:2-12.
38. Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X: Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J 2008, 55:11-21. (Pubitemid 351520175)
39. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, Sandri M: Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009, 296:C1248-57.
40. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ: Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009, 296:C1258-70.
41. Lokireddy S, McFarlane C, Ge X, Zhang H, Sze SK, Sharma M, Kambadur R: Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanismduring skeletal muscle wasting. Mol Endocrinol 2011, 25:1936-49.
42. Rodriguez J, Vernus B, Toubiana M, Jublanc E, Tintignac L, Leibovitch S, Bonnieu A: Myostatin inactivation increases myotube size through regulation of translational initiation machinery. J Cell Biochem 2011, 112:3531-42.
43. Lagirand-Cantaloube J, Offner N, Csibi A, Leibovitch MP, Batonnet- Pichon S, Tintignac LA, Segura CT, Leibovitch SA: The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J 2008, 27:1266-76. (Pubitemid 351574748)
44. Amirouche A, Durieux A, Banzet S, Koulmann N, Bonnefoy R, Mouret C, Bigard X, Peinnequin A, Freyssenet D: Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology 2009, 150:286-94.
45. Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH, Kull FC, Gonzalez-Cadavid N: Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab 2001, 280:E221-8.
46. Welle S, Bhatt K, Pinkert CA: Myofibrillar protein synthesis in myostatin-deficient mice. Am J Physiol Endocrinol Metab 2006, 290: E409-15. (Pubitemid 43671685)
47. Welle S, Burgess K, Mehta S: Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice. Am J Physiol Endocrinol Metab 2009, 296:E567-72.
48. Welle S, Mehta S, Burgess K: Effect of postdevelopmental myostatin depletion on myofibrillar protein metabolism. Am J Physiol Endocrinol Metab 2011, 300:E993-E1001.
49. Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WMH, Ma H, Pierre P, Pasternack A, Kainulainen H, Ritvos O: Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins. Am J Physiol Endocrinol Metab 2013, 304:E41-50.
50. Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M: Mechanisms regulating skeletal muscle growth and atrophy. FEBS J 2013, 280:4294-314.
51. Lokireddy S, Mouly V, Butler-Browne G, Gluckman PD, Sharma M, Kambadur R, McFarlane C: Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitinproteasome pathway-mediated loss of sarcomeric proteins. Am J Physiol Cell Physiol 2011, 301:C1316-24.
52. Lokireddy S, Wijesoma IW, Sze SK, McFarlane C, Kambadur R, Sharma M: Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting. Am J Physiol Cell Physiol 2012, 303:C512-29.
53. Goodman CA, McNally RM, Hoffmann FM, Hornberger TA: Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo. Mol Endocrinol 2013, 27:1946-57.
54. Hitachi K, Nakatani M, Tsuchida K: Myostatin signaling regulates Akt activity via the regulation of miR-486 expression. Int J Biochem Cell Biol 2014, 47:93-103.
55. Mueller TD, Nickel J: Promiscuity and specificity in BMP receptor activation. FEBS Lett 2012, 586:1846-59.
56. Sartori R, Schirwis E, Blaauw B, Bortolanza S, Zhao J, Enzo E, Stantzou A, Mouisel E, Toniolo L, Ferry A, Stricker S, Goldberg AL, Dupont S, Piccolo S, Amthor H, Sandri M: BMP signaling controls muscle mass. Nat Genet 2013, 45:1309-18.
57. Winbanks CE, Chen JL, Qian H, Liu Y, Bernardo BC, Beyer C, Watt KI, Thomson RE, Connor T, Turner BJ, McMullen JR, Larsson L, McGee SL, Harrison CA, Gregorevic P: The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J Cell Biol 2013, 203:345-57.
58. Moresi V, Williams AH, Meadows E, Flynn JM, Potthoff MJ, McAnally J, Shelton JM, Backs J, KleinWH, Richardson JA, Bassel-Duby R,Olson EN: Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell 2010, 143:35-45.
59. Wang X, Devaiah SP, Zhang W, Welti R: Signaling functions of phosphatidic acid. Prog Lipid Res 2006, 45:250-78.
60. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J: Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001, 294:1942-5. (Pubitemid 33101594)
61. Park I, Bachmann R, Shirazi H, Chen J: Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. J Biol Chem 2002, 277:31423-9. (Pubitemid 34968942)
62. Avila-Flores A, Santos T, Rincón E, Mérida I: Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid. J Biol Chem 2005, 280:10091-9. (Pubitemid 40395861)
63. Tang W, Yuan J, Chen X, Gu X, Luo K, Li J, Wan B, Wang Y, Yu L: Identification of a novel human lysophosphatidic acid acyltransferase, LPAAT-theta, which activates mTOR pathway. J Biochem Mol Biol 2006, 39:626-35. (Pubitemid 44714544)
64. O'Neil TK, Duffy LR, Frey JW, Hornberger TA: The role of phosphoinositide 3-kinase and phosphatidic acid in the regulation of mammalian target of rapamycin following eccentric contractions. J Physiol (Lond) 2009, 587:3691-701.
65. You JS, Frey JW, Hornberger TA: Mechanical stimulation induces mTOR signaling via an ERK-independent mechanism: implications for a direct activation of mTOR by phosphatidic acid. PLoS ONE 2012, 7:e47258.
66. Foster DA: Regulation of mTOR by phosphatidic acid? Cancer Res 2007, 67:1-4.
67. Ballou LM, Jiang Y, Du G, Frohman MA, Lin RZ: Ca(2+)- and phospholipase D-dependent and -independent pathways activate mTOR signaling. FEBS Lett 2003, 550:51-6. (Pubitemid 37281356)
68. Hornberger TA, Chu WK, Mak YW, Hsiung JW, Huang SA, Chien S: The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. Proc Natl Acad Sci USA 2006, 103:4741-6.
69. Takahara T, Hara K, Yonezawa K, Sorimachi H, Maeda T: Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region. J Biol Chem 2006, 281:28605-14. (Pubitemid 44507003)
70. Ha SH, Kim D, Kim I, Kim JH, Lee MN, Lee HJ, Kim JH, Jang SK, Suh P, Ryu SH: PLD2 forms a functional complex with mTOR/raptor to transduce mitogenic signals. Cell Signal 2006, 18:2283-91. (Pubitemid 44636169)
71. Yoon M, Sun Y, Arauz E, Jiang Y, Chen J: Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect. J Biol Chem 2011, 286:29568-74.
72. Veverka V, Crabbe T, Bird I, Lennie G, Muskett FW, Taylor RJ, Carr MD: Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 2008, 27:585-95. (Pubitemid 351158903)
73. Jaafar R, de Larichaudy J, Chanon S, Euthine V, Durand C, Naro F, Bertolino P, Vidal H, Lefai E, Némoz G: Phospholipase D regulates the size of skeletal muscle cells through the activation of mTOR signaling. Cell Commun Signal 2013, 11:55.
74. You J, Lincoln HC, Kim C, Frey JW, Goodman CA, Zhong X, Hornberger TA: The Role of Diacylglycerol Kinase z and Phosphatidic Acid in the Mechanical Activation of Mammalian Target of Rapamycin (mTOR) Signaling and Skeletal Muscle Hypertrophy. J Biol Chem 2014, 289:1551-63.
75. Goodman CA, Mabrey DM, Frey JW, Miu MH, Schmidt EK, Pierre P, Hornberger TA: Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. FASEB J 2011, 25:1028-39.
76. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412. (Pubitemid 38534545)
77. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004, 14:395-403. (Pubitemid 38591410)
78. Jaafar R, Zeiller C, Pirola L, Di Grazia A, Naro F, Vidal H, Lefai E, Némoz G: Phospholipase D regulates myogenic differentiation through the activation of both mTORC1 and mTORC2 complexes. J Biol Chem 2011, 286:22609-21.
79. O'Neil TK, Duffy LR, Frey JW, Hornberger TA: The role of phosphoinositide 3-kinase and phosphatidic acid in the regulation of mammalian target of rapamycin following eccentric contractions. J Physiol (Lond) 2009, 587:3691-701.
80. Su W, Yeku O, Olepu S, Genna A, Park J, Ren H, Du G, Gelb MH, Morris AJ, Frohman MA: 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol 2009, 75:437-46.
81. Yanase Y, Carvou N, Frohman MA, Cockcroft S: Reversible bleb formation in mast cells stimulated with antigen is Ca2+/calmodulin-dependent and bleb size is regulated by ARF6. Biochem J 2010, 425:179-93.
82. Sato T, Hongu T, Sakamoto M, Funakoshi Y, Kanaho Y: Molecular mechanisms of N-formyl-methionyl-leucyl-phenylalanineinduced superoxide generation and degranulation in mouse neutrophils: phospholipase D is dispensable. Mol Cell Biol 2013, 33:136-45.